Reference : Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients
De Wit, S. [Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium]
Florence, Eric mailto [Institute of Tropical Medicine, Antwerp > Department of Clinical Sciences > > >]
Vandekerckhove, L. [University Hospital Ghent, Ghent, Belgium]
Vandercam, B. [Saint-Luc University Hospital, Brussels, Belgium]
Goffard, J.-C. [University Hospital Erasme, Brussels, Belgium]
Van Wijngaerden, E. [University Hospital Leuven, Leuven, Belgium]
Moutschen, Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén. >]
Demeester, R. [University Hospital Charleroi, Charleroi, Belgium]
Thilakarathne, P. [Statistical Department, Janssen-Cilag NV, Beerse, Belgium]
Piryns, H. [Medical Department, Janssen-Cilag NV, Beerse, Belgium]
for the BREACH* Consortium [> >]
Acta Clinica Belgica
Taylor and Francis Ltd.
Yes (verified by ORBi)
[en] Belgium ; HAART (highly active antiretroviral therapy) ; HIV (human immunodeficiency virus)
[en] Background: Once daily (QD) ritonavir or cobicistat-boosted darunavir (DRV/b), in combination with other antiretrovirals (ARVs), is recommended as a first-line option for human immunodeficiency virus-infected patients in European and USA guidelines. The objective of this study was to analyse the outcomes of DRV/r QD-based antiretroviral therapy (ART) regimens in real-life settings. Methods: This is an observational, non-interventional, non-comparative, retrospective, multicentre cohort study. Data were collected from the databases of eight Belgian AIDS Reference Centres. All patients who received at least one dose of DRV/r QD, regardless of background ARV regimen, with a minimum follow-up of 6 months were included. Results: Data from 1701 subjects were collected. Most were male (66.5%) with a mean age of 42.9 years, 33.1% were treatment-naïve and 66.9% were ART experienced. During a median follow-up of 2.45 years (95% CI: 1.50–3.34), the probability to remain on treatment was 87% for the first year, 79% for the second year. DRV/r was well tolerated with few discontinuations due to adverse events (6.9%) or virological failure (0.8%). Among the 1138 treatment-experienced patients, 111 (9.8%) patients received DRV/r QD monotherapy. Conclusions: This retrospective cohort analysis confirms the long-term effectiveness and good tolerability of DRV/r QD in a real-life setting. No unexpected adverse events were reported. © Acta Clinica Belgica 2018

File(s) associated to this reference

Fulltext file(s):

Open access
dewit2018.pdfPublisher postprint1.05 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.